Company: BGLC
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001477932-25-008343
Chunk: 1

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---
10,433,848 

See accompanying notes to the consolidated financial statements.

 4Table of Contents

PART I — FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS (CONT’D)

BIONEXUS GENE LAB CORP. 

CONDENSED CONSOLIDATED BALANCE SHEETS 

AS OF SEPTEMBER 30, 2025 AND DECEMBER 31, 2024  

(Currency expressed in United States Dollars (“US$”))

     As of   Note  September 30,  December 31,      2025  2024      (Unaudited)  (Audited) LIABILITIES AND STOCKHOLDERS’ EQUITY         CURRENT LIABILITIES         Trade payables   8   184,600   1,503,326 Other payables and accrued liabilities      375,380   284,108 Current portion of operating lease liabilities  5   56,803   50,816 Advance payment from customer      11,264   95,879 Amount owing to directors      49,976   17,174 Total current liabilities      678,023   1,951,303              NON-CURRENT LIABILITIES            Non-current portion of operating lease liabilities  5   126,943   159,741 Deferred tax liabilities  4   -   - Total non-current liabilities      126,943   159,741 TOTAL LIABILITIES     $804,966  $2,111,044              STOCKHOLDERS’ EQUITY            As at September 30, 2025, common stock, no par value; 300,000,000 shares authorized and 1,796,597 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding. As at December 31, 2024, common stock, no par value; 300,000,000 shares authorized and 1,796,766 shares outstanding, and preferred stock, no par value; 30,000,000 share authorized and no shares outstanding (on a post-reverse stock split basis)*.  12  $17,331,810  $17,332,315 Additional paid in